title: Preparation and evaluation of microemulsion-based transdermal delivery of total flavone of rhizoma arisaematis.
abstract: The aims of the present study were to investigate the skin permeation and cellular uptake of a microemulsion (ME) containing total flavone of rhizoma arisaematis (TFRA), and to evaluate its effects on skin structure. Pseudo-ternary phase diagrams were constructed to evaluate ME regions with various surfactants and cosurfactants. Eight formulations of oil-in-water MEs were selected as vehicles, and in vitro skin-permeation experiments were performed to optimize the ME formulation and to evaluate its permeability, in comparison to that of an aqueous suspension. Laser scanning confocal microscopy and fluorescent-activated cell sorting were used to explore the cellular uptake of rhodamine 110-labeled ME in human epidermal keratinocytes (HaCaT) and human embryonic skin fibroblasts (CCC-ESF-1). The structure of stratum corneum treated with ME was observed using a scanning electron microscope. Furthermore, skin irritation was tested to evaluate the safety of ME. ME formulated with 4% ethyl oleate (weight/weight), 18% Cremophor EL (weight/weight), and 18% Transcutol P, with 1% Azone to enhance permeation, showed good skin permeability. ME-associated transdermal fluxes of schaftoside and isoschaftoside, two major effective constituents of TFRA, were 3.72-fold and 5.92-fold higher, respectively, than those achieved using aqueous suspensions. In contrast, in vitro studies revealed that uptake by HaCaT and CCC-ESF-1 cells was lower with ME than with an aqueous suspension. Stratum corneum loosening and shedding was observed in nude mouse skin treated with ME, although ME produced no observable skin irritation in rabbits. These findings indicated that ME enhanced transdermal TFRA delivery effectively and showed good biocompatibility with skin tissue.
authors.affiliation: Department of Pharmaceutical Sciences, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
authors.forename: Li-Na
authors.initials: LN
authors.lastname: Shen
authors.affiliation: Department of Pharmaceutical Sciences, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
authors.forename: Yong-Tai
authors.initials: YT
authors.lastname: Zhang
authors.affiliation: Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
authors.forename: Qin
authors.initials: Q
authors.lastname: Wang
authors.affiliation: Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
authors.forename: Ling
authors.initials: L
authors.lastname: Xu
authors.affiliation: Department of Pharmaceutical Sciences, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
authors.forename: Nian-Ping
authors.initials: NP
authors.lastname: Feng
mesh_terms: D000818:Animals; D002460:Cell Line; D004337:Drug Carriers / Q000737:chemistry* / Q000493:pharmacokinetics* / Q000633:toxicity; D004365:Drugs, Chinese Herbal / Q000737:chemistry* / Q000493:pharmacokinetics* / Q000633:toxicity; D004655:Emulsions / Q000737:chemistry / Q000493:pharmacokinetics / Q000633:toxicity; D006027:Glycosides; D006801:Humans; D008819:Mice, Nude; D053758:Nanoparticles / Q000737:chemistry* / Q000633:toxicity; D051381:Rats; D017207:Rats, Sprague-Dawley; D012867:Skin / Q000187:drug effects; D012869:Skin Absorption / Q000187:drug effects*; D012995:Solubility
chemical_list: D004337:Drug Carriers; D004365:Drugs, Chinese Herbal; D004655:Emulsions; D006027:Glycosides; C515112:schaftoside; C515113:isoschaftoside
keywords: cellular uptake; microemulsion; nanocarrier; transdermal
references.citation: J Invest Dermatol. 2000 Aug;115(2):292-8
references.pmid: 10951249
references.citation: Toxicol In Vitro. 2014 Aug;28(5):742-50
references.pmid: 24625437
references.citation: Int J Pharm. 2013 Sep 10;453(2):569-78
references.pmid: 23792042
references.citation: Int J Pharm. 2006 Dec 11;327(1-2):58-64
references.pmid: 16926077
references.citation: Mol Pharm. 2010 Aug 2;7(4):1266-73
references.pmid: 20545350
references.citation: Int J Pharm. 2013 Aug 16;452(1-2):201-10
references.pmid: 23680734
references.citation: J Control Release. 2011 Jan 20;149(2):159-67
references.pmid: 20950659
references.citation: Int J Pharm. 2006 Sep 14;321(1-2):117-23
references.pmid: 16876972
references.citation: Pharm Dev Technol. 2014 May;19(3):373-84
references.pmid: 23634780
references.citation: Int J Nanomedicine. 2012;7:2465-72
references.pmid: 22679361
references.citation: Drug Deliv. 2014 Mar;21(2):130-9
references.pmid: 24028295
references.citation: Pharmaceutics. 2014 Feb 28;6(1):52-77
references.pmid: 24590260
references.citation: Skin Pharmacol Physiol. 2008;21(5):246-59
references.pmid: 18562799
references.citation: Am J Chin Med. 2011;39(5):981-98
references.pmid: 21905287
references.citation: Drug Dev Ind Pharm. 2009 May;35(5):525-47
references.pmid: 19016057
references.citation: AAPS PharmSciTech. 2007 Dec 14;8(4):E104
references.pmid: 18181525
references.citation: Eur J Pharm Sci. 2002 Sep;16(4-5):237-46
references.pmid: 12208453
references.citation: Int J Nanomedicine. 2011;6:2469-82
references.pmid: 22072882
references.citation: Pharm Dev Technol. 2013 Jul-Aug;18(4):834-43
references.pmid: 23030413